Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
10 Energizing Vocations in the Innovation Business - 2Posts falsely claim Netanyahu video fabricated to cover up his death
- 3Old age isn’t a modern phenomenon – many people lived long enough to grow old in the olden days, too
- 4Bad flu season getting worse; skyrocketing cases set state record
- 5Must-See Public Parks from Around the Globe
- How federal officials talk about health is shifting in troubling ways – and that change makes me worried for my autistic child
- France bans Muslim gathering citing risk to participants
- The Developing Nearby Food Development and Its Advantages
- Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection.
- 6 Fun Urban areas For Seniors To Travel
- Surprising links between autism, Alzheimer’s could change how we treat both
- Relive NASA's historic Artemis 2 launch to the moon in these stunning photos
- Vote In favor of Feasible Way You Prescribe to Shop for Garments
- Novo Nordisk cuts Wegovy price as CEO pledges to go 'all in' on weight loss pill
